These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 25864651

  • 21. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.
    Oncotarget; 2015 Mar 30; 6(9):6597-610. PubMed ID: 25788264
    [Abstract] [Full Text] [Related]

  • 22. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
    Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D.
    BMC Cancer; 2009 May 11; 9():142. PubMed ID: 19432987
    [Abstract] [Full Text] [Related]

  • 23. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
    Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA.
    Melanoma Res; 2011 Feb 11; 21(1):44-56. PubMed ID: 20216471
    [Abstract] [Full Text] [Related]

  • 24. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Aug 11; 10(2):931-8. PubMed ID: 24840891
    [Abstract] [Full Text] [Related]

  • 25. Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation.
    Hao J, Yang X, Ding XL, Guo LM, Zhu CH, Ji W, Zhou T, Wu XZ.
    Sci Rep; 2016 Sep 09; 6():32809. PubMed ID: 27609096
    [Abstract] [Full Text] [Related]

  • 26. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.
    Breast Cancer Res Treat; 2011 Sep 09; 129(2):387-400. PubMed ID: 21046231
    [Abstract] [Full Text] [Related]

  • 27. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
    Veschi S, De Lellis L, Florio R, Lanuti P, Massucci A, Tinari N, De Tursi M, di Sebastiano P, Marchisio M, Natoli C, Cama A.
    J Exp Clin Cancer Res; 2018 Sep 21; 37(1):236. PubMed ID: 30241558
    [Abstract] [Full Text] [Related]

  • 28. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
    Hu YP, Patil SB, Panasiewicz M, Li W, Hauser J, Humphrey LE, Brattain MG.
    Cancer Res; 2008 Oct 01; 68(19):8004-13. PubMed ID: 18829558
    [Abstract] [Full Text] [Related]

  • 29. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway.
    Yang ZP, Zhao Y, Huang F, Chen J, Yao YH, Li J, Wu XN.
    World J Gastroenterol; 2015 Sep 28; 21(36):10385-99. PubMed ID: 26420965
    [Abstract] [Full Text] [Related]

  • 30. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
    Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M.
    Prostate; 2008 Jun 15; 68(9):965-74. PubMed ID: 18361408
    [Abstract] [Full Text] [Related]

  • 31. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O.
    J Transl Med; 2016 Feb 09; 14():46. PubMed ID: 26861698
    [Abstract] [Full Text] [Related]

  • 32. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
    Lu YY, Jing DD, Xu M, Wu K, Wang XP.
    World J Gastroenterol; 2008 Sep 21; 14(35):5403-11. PubMed ID: 18803351
    [Abstract] [Full Text] [Related]

  • 33. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
    El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH.
    Cancer Res; 2006 Nov 01; 66(21):10553-9. PubMed ID: 17079479
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF.
    Drug Des Devel Ther; 2015 Nov 01; 9():487-508. PubMed ID: 25609923
    [Abstract] [Full Text] [Related]

  • 35. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
    Tsai JP, Lee CH, Ying TH, Lin CL, Lin CL, Hsueh JT, Hsieh YH.
    Oncotarget; 2015 Oct 06; 6(30):28851-66. PubMed ID: 26311737
    [Abstract] [Full Text] [Related]

  • 36. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
    Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH, Chen LT, Kung HJ, Wang HD, Chuu CP.
    Oncotarget; 2015 Mar 30; 6(9):6684-707. PubMed ID: 25788262
    [Abstract] [Full Text] [Related]

  • 37. Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.
    Dao P, Smith N, Scott-Algara D, Garbay C, Herbeuval JP, Chen H.
    Cancer Lett; 2015 Apr 28; 360(1):48-59. PubMed ID: 25684663
    [Abstract] [Full Text] [Related]

  • 38. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.
    Breast Cancer Res Treat; 2010 Sep 28; 123(2):387-96. PubMed ID: 19946741
    [Abstract] [Full Text] [Related]

  • 39. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
    Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H.
    Clin Cancer Res; 2011 May 01; 17(9):2744-56. PubMed ID: 21385921
    [Abstract] [Full Text] [Related]

  • 40. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
    Torres C, Linares A, Alejandre MJ, Palomino-Morales RJ, Delgado JR, Perales S.
    Pancreas; 2016 Feb 01; 45(2):269-80. PubMed ID: 26495790
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.